全球免疫疗法药物市场规模、份额、趋势和成长分析报告（2026-2034年）

预计免疫疗法药物市场将从 2025 年的 1,804 亿美元成长到 2034 年的 3,455.8 亿美元，2026 年至 2034 年的复合年增长率为 7.49%。

由于癌症和自体免疫疾病的日益普遍，全球免疫疗法市场正经历快速扩张。免疫疗法利用人体自身的免疫系统对抗疾病，提供标靶且持久的治疗效果。查核点抑制剂和单株抗体的核准不断增加，显着推动了市场成长。医疗保健支出的增加和诊断能力的提升，进一步促进了已开发市场和新兴市场对免疫疗法的采用。

关键成长要素包括生物製药研究和个人化医疗方法的进步。製药公司正大力投资临床试验，以拓展有疗法的适应症。将免疫疗法与化疗或放射线治疗结合的联合疗法也发展迅速。此外，支援性的法规结构和快速核准机制正在加速产品商业化进程。

随着细胞疗法和癌症疫苗的进步，未来前景十分光明。免疫疗法药物在感染疾病和慢性病领域的应用拓展将扩大市场范围，而开发中国家医疗资源的改善也将进一步刺激需求。在科学突破的驱动下，免疫疗法药物市场可望保持强劲的长期成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球免疫疗法药物市场：依药物类型划分

• 市场分析、洞察与预测
• 单株抗体
• 免疫调节剂
• 细胞疗法
• 其他（疫苗等）

第五章 全球免疫疗法药物市场：依治疗领域划分

• 市场分析、洞察与预测
• 癌症
• 自体免疫疾病
• 感染疾病
• 其他的

第六章 全球免疫疗法药物市场：依分销管道划分

• 市场分析、洞察与预测
• 零售药房
• 网路药房
• 医院药房

第七章 全球免疫疗法药物市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 亚太其他地区
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Bristol Myers Squibb
  • Merck & Co. Inc
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc
  • Amgen Inc
  • Gilead Sciences
  • Regeneron Pharmaceuticals Inc
  • Eli Lilly And Company

The Immunotherapy Drugs Market size is expected to reach USD 345.58 Billion in 2034 from USD 180.40 Billion (2025) growing at a CAGR of 7.49% during 2026-2034.

The Global Immunotherapy Drugs market has experienced rapid expansion due to growing prevalence of cancer and autoimmune diseases. Immunotherapy harnesses the body's immune system to fight disease, offering targeted and durable treatment outcomes. Increasing approval of checkpoint inhibitors and monoclonal antibodies has significantly strengthened market growth. Rising healthcare expenditure and improved diagnostic capabilities further support widespread adoption across developed and emerging regions.

Key growth drivers include advancements in biologics research and personalized medicine approaches. Pharmaceutical companies are investing heavily in clinical trials to expand indications for existing therapies. Combination treatments integrating immunotherapy with chemotherapy or radiation are gaining momentum. Additionally, supportive regulatory frameworks and fast-track approvals accelerate product commercialization.

Future prospects remain highly promising as innovation in cell-based therapies and cancer vaccines advances. Expanding applications in infectious and chronic diseases will broaden the market scope. Improved accessibility in developing economies will further stimulate demand. The immunotherapy drugs market is expected to maintain strong long-term growth driven by scientific breakthroughs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Monoclonal Antibodies
• Immunomodulators
• Cell Therapy
• Others (Vaccines, etc.)

By Therapy Area

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

COMPANIES PROFILED

• Bristol Myers Squibb, Merck Co Inc, F HoffmannLa Roche AG, Novartis AG, AstraZeneca, Pfizer Inc, Amgen Inc, Gilead Sciences, Regeneron Pharmaceuticals Inc, Eli Lilly and Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others (Vaccines, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY THERAPY AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy Area
• 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Therapy Area
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Therapy Area
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Therapy Area
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Therapy Area
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Therapy Area
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Bristol Myers Squibb
  • 9.2.2 Merck & Co. Inc
  • 9.2.3 F. Hoffmann-La Roche AG
  • 9.2.4 Novartis AG
  • 9.2.5 AstraZeneca
  • 9.2.6 Pfizer Inc
  • 9.2.7 Amgen Inc
  • 9.2.8 Gilead Sciences
  • 9.2.9 Regeneron Pharmaceuticals Inc
  • 9.2.10 Eli Lilly And Company